Commerzbank Aktiengesellschaft FI Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Commerzbank Aktiengesellschaft FI increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 453.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,850 shares of the pharmaceutical company’s stock after purchasing an additional 8,069 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Vertex Pharmaceuticals were worth $4,386,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Daymark Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals in the first quarter worth $226,000. Farther Finance Advisors LLC raised its holdings in Vertex Pharmaceuticals by 19.2% in the first quarter. Farther Finance Advisors LLC now owns 2,871 shares of the pharmaceutical company’s stock worth $1,392,000 after purchasing an additional 462 shares during the period. GAMMA Investing LLC raised its holdings in shares of Vertex Pharmaceuticals by 25.1% during the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock worth $2,425,000 after acquiring an additional 1,005 shares during the period. Finally, Simplicity Wealth LLC raised its holdings in shares of Vertex Pharmaceuticals by 80.9% during the first quarter. Simplicity Wealth LLC now owns 1,299 shares of the pharmaceutical company’s stock worth $630,000 after acquiring an additional 581 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

VRTX opened at $414.86 on Friday. The company’s 50-day moving average is $394.99 and its 200 day moving average is $440.30. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The firm has a market capitalization of $106.37 billion, a P/E ratio of 29.65 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VRTX. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Evercore ISI reduced their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a report on Thursday, September 11th. Guggenheim cut their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, Stifel Nicolaus dropped their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $494.43.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.